Sitemap
- Mixed news
- 07: BioPorto’s NGAL test approved for use by leading U.S. reference laboratory
- 06: BioPorto’s patent rights for NGAL - opposition to the European patent
- Newsletter July 2010
- 05: Interim financial report Q1
- 04: Development of Annual General Meeting
- 03: Insider's dealings
- 02: Annual General Meeting
- 01: Annual Report 2009
- Newsletter January 2010
- 29: Financial calendar 2010
- 28: Interim financial report for Q3 2009
- 27: Share Capital and Votes
- 26: EPO decides to issue BioPorto’s NGAL cutoff patent on November 11, 2009
- 25: Company articles
- 24: BioPorto completes cash issue
- 23: CCH drops lawsuit
- 22: Cash issue, private placement
- 21: Interim Financial Report for Q2 2009
- Documentation: EPO's reply to 3rd party
- 20: BioPorto adopts new rapid route to widespread commercialization of kidney test
- 19: EPO maintains October 1, 2009, as the date of resumption of patent grant proceedings
- 18: Objections from CCH against the resumption of grant proceedings
- 17: Insider's dealings
- 16: Insider's dealings
- 15: Insider's dealings
- 14: Interim financial report for Q1
- 13: Change of date for resumption
- 12: Resumption of proceedings for BioPorto's patent
- 11: Issue of warrants in BioPorto A/S
- 10: Insider's dealings
- 09: Development of annual general meeting
- 08: Insider's dealings
- 07: Insider's dealings
- 06: Insider's dealings
- 05: Insider's dealings
- 04: Annual General Meeting
- 03: Launch of APC-PCI ELISA Kit
- 02: Annual Report 2008
- 01: BioPorto's cutoff patent for NGAL – grant proceedings stayed
- Newsletter 01, 2009
- Products
- Bioporto Diagnostics
- Antibodyshop
- Alphabetical list
- Cell biology
- Coagulation
- Collectins and related products
- Complement
- Complement component C1-inhibitor (C1INH)
- Complement component C1s (human, pro- and activated enzyme)
- Complement component C2 (human)
- Complement component C3
- Complement component C4 (human)
- Complement component C5 (human)
- Complement component C5b-9 (human)
- Complement component C9 (human)
- Complement factor B
- Complement factor D (human)
- Complement factor H
- Complement factor I (human)
- Mannan-binding lectin
- Properdin
- Cytokines and hormones
- Adrenomedullin (human)
- alpha-calcitonin gene-related peptide (alpha-CGRP)
- Chorionic gonadotrophin (human, hCG)
- Estrogens
- Exendin-4
- Gastric inhibitory polypeptide (GIP)
- Ghrelin (human, rat)
- Glucagon-like peptide-1 (GLP-1)
- Glucagon-like peptide-2 (human, hGLP-2)
- Leptin
- Neuropeptide Y
- Pancreatic Polypeptide (human, PP)
- Peptide histidine-methionine (PHM)
- Peptide YY (human, PYY)
- Tumor necrosis factor alpha (TNF alpha)
- Vasoactive intestinal peptide (VIP)
- Enzymes
- Marker molecules
- Acetylcholinesterase
- alpha-fetoprotein (human)
- Amyloid ß-peptide
- Butyrylcholinesterase (human)
- NGAL (dog, cat, guinea pig, neutrophil gelatinase-associated lipocalin)
- NGAL (human, neutrophil gelatinase-associated lipocalin)
- NGAL (monkey, neutrophil gelatinase-associated lipocalin)
- NGAL (mouse, neutrophil gelatinase-associated lipocalin)
- NGAL (pig, neutrophil gelatinase-associated lipocalin)
- NGAL (rat, neutrophil gelatinase-associated lipocalin)
- Placental protein 14 (human, glycodelin A)
- Pregnancy associated plasma protein A (PAPP-A)
- Procollagen
- Microbiology
- Miscellaneous
- Oncology
- Other blood proteins
- Sera and Antigens
- How to buy
- All other countries
- Austria
- Bangladesh
- Belgium
- Brazil
- Canada
- China
- Czech Republic
- Denmark
- Egypt
- Finland
- France
- Germany
- Greece
- Hungary
- India
- Indonesia
- Iran
- Ireland
- Israel
- Italy
- Japan
- Korea
- Kuwait
- Luxembourg
- Malaysia
- Nepal
- Netherlands
- Norway
- Pakistan
- Philippines
- Poland
- Portugal
- Republic of Cyprus
- Russia
- Singapore
- Slovakia
- Slovenia
- Spain
- Sri Lanka
- Sweden
- Switzerland
- Taiwan
- United Kingdom
- United States
- Investors
- Announcements
- 2010
- 2009
- 29: Financial calendar 2010
- 28: Interim financial statement Q3 2009
- 27: Share Capital and Votes
- 26: EPO decides to issue BioPorto’s NGAL cutoff patent on November 11, 2009
- 25: Company articles
- 24: BioPorto completes cash issue
- 23: CCH drops lawsuit
- 22: Cash issue, private placement
- 21: Interim Financial Report for Q2 2009
- 20: BioPorto adopts new rapid route to widespread commercialization of kidney test
- 19: EPO maintains October 1, 2009, as the date of resumption of patent grant proceedings
- 18: Objections from CCH against the resumption of grant proceedings
- 17: Insider's dealings
- 16: Insider's dealings
- 15: Insider's dealings
- 14: Interim financial report for Q1
- 13: Change of date for resumption
- 12: Resumption of proceedings for BioPorto's patent
- 11: Issue of warrants in BioPorto A/S
- 10: Insider's dealings
- 09: Development of annual general meeting
- 08: Insider's dealings
- 07: Insider's dealings
- 06: Insider's dealings
- 05: Insider's dealings
- 04: Annual General Meeting
- 03: Launch of APC-PCI ELISA Kit
- 02: Annual Report 2008
- 01: BioPorto's cutoff patent for NGAL – grant proceedings stayed
- 2008
- 25: Insider's dealings
- 24: Insider’s dealings
- 23: BioPorto’s patent rights strengthened for NGAL
- 22: BioPortos patentrettigheder for NGAL
- 21: Financial calendar 2009
- 20: Insider's dealings
- 19: Interim Financial Report for Q3
- 18: Announcement from major shareholder
- 17: Announcement from major shareholder
- 16: Shares and votes
- 15: Insider's dealings
- 14: Insider's dealings
- 13: Announcement from major shareholder
- 12: Interim Financial Report for Q2 2008
- 11: BioPorto’s NGAL patent approved for issue in Europe
- 10: BioPorto launches Rat NGAL ELISA Kit
- 09: New diagnostic application of the APC-PCI test
- 08: Articles of association
- 07: Interim financial statement, first quarter 2008
- 06: Issue of warrants in BioPorto A/S
- 05: Devl. of Annual General Meeting
- 04: Annual General Meeting
- 03: Annual Report 2007
- 02: Financial calendar
- 01: Name change in affiliate
- 2007
- 29: Settlement between SSI and BioPorto
- 28: Insider's dealings
- 27: Interim financial statement
- 26: Devl. of extraordinary general meeting
- 25: Insider's dealings
- 24: Stock capital and votes
- 23: Extraordinary general meeting
- 22: Articles of association
- 21: Exercise of warrants
- 20: Prospectus
- 19: Prospectus Announcement
- 18: Stock capital and votes
- 17: BioPorto continues negotiations
- 16: Insider's dealings
- 15: Devl. of annual general meeting
- 14: Notification from major shareholder
- 13: BioPorto to issue new shares in a directs placement
- 12: Annual general meeting
- 11: Insider's dealings
- 10: Insider's dealings
- 09: Annual report
- 08: Status: NGAL patent
- 07: Devl. of extraordinary general meeting
- 06: Extraordinary general meeting
- 05: Financial calendar 2007 (corrected)
- 04: Fondsrådets afgørelser mv.
- 03: Akkvistition af Merlin
- 02: Alternativ indregning af cellelinier
- 01: Financial Calendar 2007
- 2006
- 22: Status: Akkvisitioner og fokusområder
- 21: Kontant rettet emission – T.DKK 20.000
- 20: NGAL hurtig analyse lancering
- 19: Fondsrådets 2. afgørelse, fuld længde
- 18: Fondsrådets 2. afgørelse
- 17: Korrigerende info til delårsrapport 2006
- 16: Korrigerende info til årsrapport 2004 og 2005
- 15: Fondsrådets afgørelse
- 14: Halvårsrapport 2006
- 13: Fondsrådets regnskabskontrol
- 12: Interface Biotech forhandling
- 11: Akkvisition Merlin Diagnostika
- 10: Warrantsprogram og kapitalforhøjelser
- 09: Insideres handler
- 08: Forløb af ordinær generalforsamling
- 07: Indkaldelse til ordinær generalforsamling
- 06: Årsrapport 2005
- 05: Insideres handler
- 04: Akkvisition af Merlin
- 03: Insideres handel
- 02: Finanskalender 2006
- 01: Akkvisitionsstatus
- 2005
- 2004
- Share information
- Newsletter
- Presentations
- Key Figures
- Financial calendar
- Corporate governance
- News mail
- Contact investor relations
- Announcements
